However, in the CheckMate 067 study it was demonstrated that the 5 year overall survival rate was 60% for BRAF mutant melanoma patients with combined ipilimumab and nivolumab therapy compared to 48% in BRAF wildtype patients, indicating a positive predictive value for BRAF mutant melanoma (Hodi et al. 2018). This evidence concerns the gene BRAF and melanoma.